News and Trends 25 May 2021 Delayed IPOs and Market Drops Batter Biotech Stocks Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has seen stock prices falling and IPOs postponed. The Covid-19 pandemic was a major disruption for stock markets across the globe at the start of 2020. However, markets like Euronext and the tech-focused Nasdaq rallied and […] May 25, 2021 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2021 Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions The US medtech firm Hologic has bought the Finnish-French biotech Mobidiag for around €668M in the latest of a series of mergers, acquisitions, and stock market launches taking over the diagnostics market. Hologic’s move is the latest in a flurry of activity from the women’s health specialist, which has snapped up Diagenode in Belgium, Biotheranostics […] April 20, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2021 Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells The Dutch biotech startup Lava Therapeutics launched onto the Nasdaq stock market last week with an €85.6M ($100.5M) IPO. This is a sign of mounting investor interest in cancer treatments based on immune cells known as gamma delta T cells. The proceeds of the IPO will be used to drive the development of the company’s […] March 31, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Expert Advice 26 Oct 2020 How to Prepare for a Successful Biotech IPO Any biotech company that has reached a certain size and is in need of investment will have to consider the critical question: is it time to go public? Navigating the stock market can be particularly challenging for biotech companies. The biotech industry has some unique requirements that sets it apart from, say, tech or real […] October 26, 2020 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2020 Update: ADC Therapeutics’ IPO Hits Above Target with €215M Update (15/05/2020): The Swiss biotech ADC Therapeutics has priced its IPO on the New York Stock Exchange far above the initial target of €172M, raising a total of €215.2M ($232.7M). ADC Therapeutics ended up offering more than 12 million shares at a price of €17.57 ($19) per share, which was higher than the €16.65 ($18) […] May 15, 2020 - 4 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2019 €51M Nasdaq IPO Will Fund Centogene’s Rare Disease Diagnostics The German company Centogene has raised €50.6M ($56M) in an IPO on the Nasdaq Stock Exchange to fund the development of diagnostics technology that could improve the treatment of rare diseases. The fundraise fell under Centogene’s target value of €54M ($60M). A part of the proceeds will fuel the development of biomarkers that Centogene will […] November 7, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2019 Innate Pharma Raises €62M IPO to Develop Antibody Drugs for Cancer The French company Innate Pharma has raised a Nasdaq IPO of €62.1M ($68.8M) to fund the development of antibody immunotherapies for solid tumors and blood cancer. Innate Pharma’s lead candidate antibody monalizumab is being co-developed in phase II with AstraZeneca for the treatment of head and neck cancer and colorectal cancer. Monalizumab is a member […] October 17, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2019 ADC Therapeutics Cancels Nasdaq IPO Amidst Market Growth Fears The Swiss biotech ADC Therapeutics has withdrawn its application for a €182M ($200M) Nasdaq IPO, citing adverse market conditions caused by global manufacturing slowdowns. ADC Therapeutics declined to comment on the specific market situation. Its withdrawal is likely due to slumps in European and US stock markets seen earlier this week caused by drops in […] October 4, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2019 Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs The Danish biotech Genmab has made a big splash on the Nasdaq, raising a €450M ($506M) IPO to fuel its antibody drug programs in cancer, autoimmune diseases, and more. This IPO is one of the biggest in biotech history, behind the whopping €530M Nasdaq entry from US mRNA biotech Moderna last year. It’s also to […] July 18, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2018 Are Recent IPO Delays Bad News for European Biotech? Over the last two weeks, several biotech companies in Europe have decided to postpone IPOs on the stock markets — is this a sign that biotech stocks are underperforming? Since the end of October, several European biotech companies have delayed their IPOs — including Abacus Medicine on the Frankfurt stock exchange, Themis Bioscience on the […] November 13, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2017 Biotech Crosses the Channel to Raise €9.7M for its Diagnostics Tools Novacyt will use the money raised on the AIM market, London, to expand its manufacturing capacity and continue research looking into new techniques. Novacyt specializes in diagnostic tools for a number of indications, including cancer and infectious diseases. Today, it has announced that it has raised €9.7M by placing stocks on the London-based Alternative Investment Market (AIM). […] October 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2017 Ablynx Launches $175M IPO on Wall Street After Phase III Success Fresh from announcing positive Phase III results, Ablynx has wasted no time in filing a $175M (€148M) IPO to continue developing its nanobodies technology. On Monday, the Belgian biotech shared the news that its nanobody, caplacizumab, received encouraging results for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a life-threatening blood disorder. This news boosted the company’s […] October 4, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email